logo-loader
Polarean Imaging PLC

City broker reckons Polarean shares are worth three times their current value

“The annual burden of pulmonary disease in the US is estimated to be over US$150bn and Polarean expects over US$500mln in system sales just to top-tier institutes,” read Northland’s note

lung x ray
Polarean’s drug-device platform can be added to existing MRI systems to achieve an improved level of lung function imaging

Broker Northland Capital has initiated coverage of shares in the medical devices specialist Polarean Imaging PLC (LON:POLX) with a 46p a share valuation.

The Northland target, derived using discounted cash flow analysis, is roughly triple the current price.

The company is currently running two phase III trials for its drug-device platforms, which analyst Vadim Alexandre believes will propel it into the lucrative pulmonary disease market, which is estimated to be worth US$150bn in the US alone.

“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients.

The shares were off 15% in early trade after it said it had conditionally raised US$4mln from investors at a price of 14p.

Those who took part in the fundraiser will no doubt be keenly interested in the Northland analysis, which speaks to the significant potential of Polarean, which listed on AIM in March.

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago

RNS

Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago

2 min read